Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

计划入组 138 人 · 首次发布于 2026 年 3 月 18 日

KAT6A Inhibitor(Insilico)

KAT6 Inhibitor (JiangSu Hengrui)

KAT6A/B inhibitors therapy(pfizer)

FDA Clears IND for Prelude Therapeutics' First-in-Class Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer

Olema's KAT6 Inhibitor OP-3136 Shows Promising Anti-Tumor Activity Across Multiple Cancer Types

Olema Oncology's KAT6 Inhibitor OP-3136 Receives FDA IND Clearance, Phase 1 Trial Planned for 2025